Open AccessKnockdown of Serine‐Arginine Protein Kinase 1 Inhibits the Growth and Migration in Renal Cell Carcinoma Cells
Author(s) -
Xingtao Han,
Jinjian Yang,
Zhiyuan Jia,
Pengtao Wei,
Han Zhang,
Wenwei Lv,
Jiantao Sun,
Qingxiang Huo
Publication year - 2017
Publication title -
oncology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.267
H-Index - 57
eISSN - 1555-3906
pISSN - 0965-0407
DOI - 10.3727/096504016x14743324568129
Subject(s) - protein kinase b , gene knockdown , pi3k/akt/mtor pathway , biology , cancer research , cell growth , kinase , phosphorylation , microbiology and biotechnology , signal transduction , cell culture , biochemistry , genetics
The pre-mRNA splicing regulator serine-arginine protein kinase 1 (SRPK1), a member of the SR kinase family, plays an essential role in cancer development and various pathophysiological processes. However, its expression pattern and functions in renal cell carcinoma (RCC) remain unknown. Therefore, the aim of this study was to assess the role of SRPK1 in RCC. Our data showed that SRPK1 was significantly upregulated in human RCC tissues and cell lines. SRPK1 interference significantly inhibited the proliferation of RCC cells and inhibited tumor growth in vivo. In addition, SRPK1 interference also suppressed migration and invasion in RCC cells. A mechanistic study showed that SRPK1 interference inhibited the phosphorylation of PI3K and Akt in RCC cells. In conclusion, our findings suggest that SRPK1 interference inhibits the growth and invasion of RCC cells through suppressing the PI3K/Akt signaling pathway. Thus, SRPK1 might be a therapeutic target for the treatment of RCC.